Watch Alex Spira, MD, PhD, FACP, FASCO discuss findings from a global Phase I study evaluating an investigational therapy for previously treated patients with EGFR-mutated non-small cell lung cancer, presented at the IASLC World Conference on Lung Cancer.
Link — Metastatic EGFR-Mutated NSCLC Global Study of Izalontamab Brenitecan – The ASCO Post



